Am­gen halts a PhI for FLT3 BiTE while re­sum­ing dos­ing on an­oth­er

Am­gen did a bit of a bal­anc­ing act for its col­umn of Phase I on­col­o­gy pro­grams dur­ing the lat­est quar­ter­ly up­date, as it dis­closed that it’s re­sumed dos­ing for pavu­ru­tam­ab (AMG 710) but halt­ed en­roll­ment to a tri­al for AMG 427. Both were BiTE mol­e­cules with ex­tend­ed half lives.

Alarmed by a safe­ty is­sue that they’ve en­coun­tered, sci­en­tists are tweak­ing the pro­to­col be­fore they can re­sume dos­ing, a spokesper­son told End­points News.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER